Literature DB >> 1347103

Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100.

D R Illingworth1, F Vakar, R W Mahley, K H Weisgraber.   

Abstract

Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant disorder associated with hypercholesterolaemia in which an aminoacid substitution in apoprotein B-100 leads to low-density lipoprotein (LDL) particles which have defective binding to the LDL receptor. All known patients are heterozygous, and their plasma contains normal and poorly binding LDL particles. 12 hypercholesterolaemic patients from 10 unrelated families with FDB were treated with lovastatin. In 6 patients treated with 20 mg lovastatin daily, LDL cholesterol decreased by 21.5% from 6.23 to 4.89 mmol/l (95% confidence interval 0.74, 1.96 mmol/l), whereas it fell by 32.1%, from 6.99 to 4.81 mmol/l (95% CI 1.55, 2.70 mmol/l), in 9 patients who received 40 mg daily. These results indicate that the hypercholesterolaemia of FDB may respond to treatment with statins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347103     DOI: 10.1016/0140-6736(92)90875-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  First International Workshop on Familial Defective apo B-100, Munich, November 1991.

Authors:  H Schuster; S Humphries; G Rauh; C Keller
Journal:  Clin Investig       Date:  1992-10

2.  Familial hypercholesterolaemia.

Authors:  A David Marais
Journal:  Clin Biochem Rev       Date:  2004-02

Review 3.  Familial defective apolipoprotein B-100: a cause of hypercholesterolemia and early coronary heart disease.

Authors:  B A Nassar
Journal:  CMAJ       Date:  1993-02-15       Impact factor: 8.262

4.  Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.

Authors:  P S Hansen; H Meinertz; L U Gerdes; I C Klausen; O Faergeman
Journal:  Clin Investig       Date:  1994-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.